Skip to main content

Advertisement

Table 1 Targets and phase of clinical development of ALK inhibitors

From: Role and targeting of anaplastic lymphoma kinase in cancer

Drug Targets Phase of clinical development References
Crizotinib ALK c-MET ROS1 Indication worldwide for therapy of NSCLC harbouring ALK gene rearrangement in first and second line • Shaw AT, et al. NEJM 2013 [32] • Solomon BJ, et al. NEJM 2014 [33]
Alectinib ALK, including ALK secondary mutationsRET - Approval from FDA (December 2015) and EMA (February 2017) in second line therapy of NSCLC harbouring ALK gene after progression to crizotinib - FDA granted fast approval in first line setting based on results of phase II and III clinical trials • Larkins E, et al. CCR 2016 [52] • Shaw AT, et al. Lancet Oncol 2016 [56] • Hida T, et al. Lancet 2017 [59] • Peters S, et al. NEJM 2017 [60]
Ceritinib ALK, including ALK secondary mutations IGF-1R ROS1 STK22D - Recent fast approval from FDA in second line therapy of NSCLC harbouring ALK gene after progression to crizotinib (May 2017) based on results of phase II clinical trials • Crinò L, et al. JCO 2016 [48] • Shaw AT, et al. JTO 2016 [47]
Brigatinib ALK, including ALK secondary mutations ROS1 EGFR NTRK1 - Recent fast approval from FDA in second line therapy of NSCLC harbouring ALK gene after progression to crizotinib (April 2017) based on results of phase II clinical trials • Markham A, et al. Drugs 2017 [61]
Lorlatanib ALK and ROS1, including all known their mutant forms Ongoing phase III trials in NSCLC first line versus crizotinib ClinicalTrials.gov, NCT03052608
Entrectinib ALK, Including ALK secondary mutations NTRK1, 2, and 3 ROS1 Ongoing phase II basket trial STARTRK-2 (NCT02568267) • Drilon A, et al. Cancer Discovery 2017 [63]